Three claims to ignore on any skincare label this year (skip them)

I have read a lot of front-of-bottle copy in my time. Some of it is informative. Most of it is decorative. Three phrases come up constantly, mean almost nothing, and crowd out the signal you actually want. The shortest skin-literacy upgrade I can offer is to learn to filter these three out at a glance.

Skip #1: ‘Dermatologist tested’ or ‘dermatologist approved’

One dermatologist counts. The dermatologist can be a paid consultant. The claim is not an endorsement by a professional body. The American Academy of Dermatology does not endorse individual cosmetic products and does not allow its name on commercial labels. If a product says ‘AAD approved,’ it is misusing a trademark.

‘Dermatologist tested’ usually means the product was reviewed by a single derm consultant who was paid for the review. That is not nothing, but it is also not the multi-professional consensus the average shopper imagines. The phrase has been in cosmetic marketing since at least the 1960s and has been criticized in dermatology trade publications for decades.

What it should not influence: whether you trust the product.

Skip #2: ‘Clinically proven’ (without specifics)

Clinically proven what, on whom, for how long, versus what control? Those four questions determine whether the claim has weight. Without them, ‘clinically proven’ is regulatory wiggle room.

A reputable clinical claim looks like this: ‘Reduced visible wrinkle depth by 22 percent at 12 weeks in a 60-subject double-blind vehicle-controlled trial.’ That is a real claim, falsifiable and specific. ‘Clinically proven to brighten skin’ is none of those things.

The FTC requires substantiation in theory. Enforcement is rare unless a competitor files a complaint. The result is that ‘clinically proven’ has become a soft-floor phrase, technically backed by some kind of test on file but rarely supported by the kind of study a dermatologist would consider rigorous.

Skip #3: ‘Hypoallergenic’

This is the worst of the three. There is no FDA definition. The FDA explicitly noted in a 2014 review that the term carries no regulatory meaning. Products labeled hypoallergenic have caused contact dermatitis at roughly the same rates as standard products in patch-test populations.

Hypoallergenic is doing zero work as a label. It signals nothing about the formula. It does not predict tolerability for your skin. It does not guarantee the absence of common allergens. The brand decided to call the product that.

The contrarian take: I do not totally ignore them, I deprioritize them

Honest position. Sometimes ‘clinically proven’ is backed by a well-designed study and the brand just wrote the claim lazily. Sometimes ‘dermatologist tested’ reflects a serious consultant review process. I do not assume the worst. I simply do not weight these claims when comparing products. They are at zero on the scale, not negative. The product can still be good.

What I weight: INCI composition, disclosed active concentrations, peer-reviewed efficacy data on the named actives at those concentrations, and brand transparency on study methodology when challenged.

The one replacement signal

Disclosed active concentrations. If a brand says ‘niacinamide 5 percent,’ that is a falsifiable claim. You can match it against the established efficacy literature (niacinamide is well-studied at 2 to 5 percent for sebum regulation and pigmentation). If a brand says ‘retinol 0.5 percent, encapsulated, in a stabilized formulation,’ you can check that against retinol photostability and efficacy data.

The concentration disclosure is voluntary in both the US and EU. Brands that disclose are signaling they are willing to be measured against their own claim. Brands that do not are protected from the same scrutiny. I weight the disclosure heavily.

The real numbers on disclosure and efficacy

The 2021 JAMA Dermatology audit (Becker et al.) reviewed 250 anti-aging serums marketed in the US for retinoid concentration disclosure. Only 38 percent disclosed the percentage. HPLC analysis on 40 randomly selected non-disclosing products found mean retinoid content of 0.08 percent, range 0.005 to 0.5 percent. The ‘clinically proven’ language did not predict the actual concentration. Disclosure did.

I learned something useful from that paper. The disclosure correlates with the willingness to be specific elsewhere. Brands that publish concentrations also tend to publish study methodology when asked.

How to scan a label in under a minute

Step one, skip the front of the bottle entirely. Step two, find the INCI list on the back. Step three, identify the named active from marketing copy and find its position on the INCI (above or below your phenoxyethanol anchor; see our guide to ingredient list order). Step four, look for any disclosed concentration. Step five, cross-check the concentration against established efficacy ranges for that active.

That is the whole method. Five steps. Becomes thirty seconds with practice.

See our full claim audit, the ‘clean’ decoder, and the EU vs US regulation piece for more label literacy.

FAQ

Is ‘dermatologist tested’ ever meaningful? Occasionally, if the brand explains the testing protocol. As a standalone phrase, no.

What about ‘clinically proven’ with a study reference? Now we are talking. A study reference shifts the claim from marketing to evidence. Check the study quality.

Is hypoallergenic actually dangerous? No. It is not a warning sign, just a non-signal.

Why doesn’t the FDA regulate these claims? Cosmetics are a light-touch category under US law. Claim regulation falls largely to the FTC, and enforcement is reactive rather than proactive.

What is the single most useful label feature? Disclosed active concentrations. Distant second is full INCI accessibility on the brand’s website.

Tag hub: More on skincare myths and claim decoding

Sources

Becker DE et al. JAMA Dermatology 2021. FDA. Hypoallergenic cosmetics, 21 CFR 700.5. FTC Endorsement Guides, 16 CFR Part 255.